Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes : A Randomized, Double-Blind, Placebo-Controlled Trial

Show full item record



Permalink

http://hdl.handle.net/10138/346501

Citation

Tougaard , N H , Frimodt-Moller , M , Salmenkari , H , Stougaard , E B , Zawadzki , A D , Mattila , I M , Hansen , T W , Legido-Quigley , C , Horkko , S , Forsblom , C , Groop , P-H , Lehto , M & Rossing , P 2022 , ' Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes : A Randomized, Double-Blind, Placebo-Controlled Trial ' , Journal of clinical medicine , vol. 11 , no. 13 , 3573 . https://doi.org/10.3390/jcm11133573

Title: Effects of Butyrate Supplementation on Inflammation and Kidney Parameters in Type 1 Diabetes : A Randomized, Double-Blind, Placebo-Controlled Trial
Author: Tougaard, Ninna H.; Frimodt-Moller, Marie; Salmenkari, Hanne; Stougaard, Elisabeth B.; Zawadzki, Andressa D.; Mattila, Ismo M.; Hansen, Tine W.; Legido-Quigley, Cristina; Horkko, Sohvi; Forsblom, Carol; Groop, Per-Henrik; Lehto, Markku; Rossing, Peter
Contributor organization: Clinicum
University of Helsinki
Nefrologian yksikkö
CAMM - Research Program for Clinical and Molecular Metabolism
HUS Abdominal Center
Research Programs Unit
Department of Medicine
Per Henrik Groop / Principal Investigator
Date: 2022-07
Language: eng
Number of pages: 13
Belongs to series: Journal of clinical medicine
ISSN: 2077-0383
DOI: https://doi.org/10.3390/jcm11133573
URI: http://hdl.handle.net/10138/346501
Abstract: Type 1 diabetes is associated with increased intestinal inflammation and decreased abundance of butyrate-producing bacteria. We investigated the effect of butyrate on inflammation, kidney parameters, HbA1c, serum metabolites and gastrointestinal symptoms in persons with type 1 diabetes, albuminuria and intestinal inflammation. We conducted a randomized placebo-controlled, double-blind, parallel clinical study involving 53 participants randomized to 3.6 g sodium butyrate daily or placebo for 12 weeks. The primary endpoint was the change in fecal calprotectin. Additional endpoints were the change in fecal short chain fatty acids, intestinal alkaline phosphatase activity and immunoglobulins, serum lipopolysaccharide, CRP, albuminuria, kidney function, HbA1c, metabolites and gastrointestinal symptoms. The mean age was 54 +/- 13 years, and the median [Q1:Q3] urinary albumin excretion was 46 [14:121] mg/g. The median fecal calprotectin in the butyrate group was 48 [26:100] mu g/g at baseline, and the change was -1.0 [-20:10] mu g/g; the median in the placebo group was 61 [25:139] mu g/g at baseline, and the change was -12 [-95:1] mu g/g. The difference between the groups was not significant (p = 0.24); neither did we find an effect of butyrate compared to placebo on the other inflammatory markers, kidney parameters, HbA1c, metabolites nor gastrointestinal symptoms. Twelve weeks of butyrate supplementation did not reduce intestinal inflammation in persons with type 1 diabetes, albuminuria and intestinal inflammation.
Subject: type 1 diabetes
intestinal inflammation
albuminuria
butyrate
intestinal alkaline phosphatase
INTESTINAL ALKALINE-PHOSPHATASE
BOWEL-DISEASE
GUT MICROBIOME
RENAL-FAILURE
INDIVIDUALS
HEALTH
DIET
3121 General medicine, internal medicine and other clinical medicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
jcm_11_03573_v2.pdf 649.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record